Innovative Directions in Health – FDA Warning Letter

The FDA reviewed www.idinhealth.com and issued a Warning Letter to Dr. Khalid Mahmud on April 5, 2010, regarding misbranded LipoDissolve products. The products are deemed drugs under 21 U.S.C. § 321(g)(1) due to claims of treating, mitigating, or preventing disease, or affecting body structure/function (e.g., "break down fat," "treat Lipomas"). As injectable products requiring professional supervision, they are also prescription drugs per 21 U.S.C. § 353(b)(1).

The website's claims cause the products to be misbranded under 21 U.S.C. §§ 352(a), 352(n), and 321(n), and 21 CFR 202.1(e)(5)(i), (e)(6)(i). Specific violations include unsubstantiated efficacy claims ("Extremely effective for fat and cellulite"), unsubstantiated superiority claims ("LipoDissolve supercedes Mesotherapy...more than twice as effective"), and unsubstantiated safety claims ("performed more than 80,000 procedures without any major side effects or death"). The FDA is unaware of evidence supporting these claims.

The letter requires prompt corrective action within fifteen working days, including a written response detailing steps taken to correct violations and prevent recurrence.